ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1743

Kawasaki Disease: Is Intravenous Immunoglobulin Alone Adequate for the Child with Kawasaki Disease and Coronary Artery Lesions? A Retrospective Study of 65 Children with Kawasaki Disease from a Single North Indian Centre

Manjari Agarwal 1, Sumidha Mittal 1, Anju Singh 1, Neeraj Agarwal 2 and Sujata Sawhney1, 1Department of pediatric rheumatology, Sir Ganga Ram Hospital, New Delhi, India, New Delhi, India, 2Sir Gangaram Hospital, New delhi, India

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Coronary Aneurysm and corticosteroids, Kawasaki disease

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Steroid use in Kawasaki disease (KD)is  controversial and has swung from contraindicated, to maybe &  now perhaps “should be given to all.”(1) Currently, standard practice is to use IVIg for all children with KD and add upfront steroids to IVIg only for those children who are at risk of non- response to IVIg , if such children can be identified. (2) There is data to support the use of  steroids at  2mg/kg/day as an add on to IVIg for the child who is at high risk of non response to the 1st IVIg (3)   At our center, over the last 18 years we have observed1. significant no. of children present with CALs & 2. These children often do not respond to  1st dose of IVIG. Thus, from 2017 we changed our practice & added steroids to IVIG as an upfront therapy to children presenting with CALs. We audited our practice & present the data on 65 children with KD.
Purpose:

  1. To study demographic & clinical profile of children with KD.
  2. To study response rate of IVIg
  3. To study the difference in response rate (if any ) for the child with KD & CALs who was given only IVIg ( pre 2017) or IVIg & steroids ( post 2017) at first presentation

Methods: All children diagnosed with KD from Jan13 to Apr19 were included. Clinical & demographic details were recorded on predesigned proformas. CALs were defined by z score (Boston) of more than 2 in any coronary artery. Response to IVIG was defined as no fever 36 hours post IVIG completion. Patients given IVIG alone got high dose aspirin, with steroids only low dose was given.SPSS 17.0 was used for analysis.

Results: 65 KD patients reviewed. Clinical & demographic details in Table 1. CALs were present in 31(47.6%) children at diagnosis. Boys had more CALs at onset than girls(p=0.059) IVIg was given to all. Steroids as first line were given to 13(20%): All had CALs. A second dose of IVIG was required by 13(20%).  Therapy detailed in Table 2.  IVIg alone had a poor response in those presenting with CALs. Addition of steroids to IVIG upfront was associated with significant increase in response in those with CALs(p=0.001) Details in table 3. No factors predicted the response to IVIG alone(age, day of diagnosis, C reactive protein). A higher z score predicted poor response to IVIG alone(p< 0.005), thus reiterating the fact that steroids are helpful in KD patients with CALs Kawasaki shock syndrome was seen in 2(3%) and macrophage activation syndrome in 1(1.5%),requiring high dose methylprednisolone(10-30mg/kg/day). At median follow up of 14 months(IQR 8-15), CALs normalized in 27(86%),5 persisted to have abnormal CALs. ( All  had giant aneurysms at presentation, Z scores >10). There was no mortality in this cohort.

Ref:

  1. Corticosteroids for the treatment of KD in children. Cochrane Review 2017.
  2. Diagnosis, Treatment, and Long-Term Management of KD. 2017.
  3. Efficacy of IVIG plus prednisolone for prevention of CALs in severe Kawasaki disease (RAISE study): Lancet 2012

Conclusion:

  1. 47% KD patients presented with CALs.
  2. KD with CALs have poor response to IVIG alone vs IVIG with upfront steroids (p=0.001)
  3. In addition to the well described scoring systems that predict a poor response to IVIG in the Japanese population, the presence of CALs and risk of non response to IVIG needs further study and replication in cohorts across the world.


table 1

Table 1: Clinical and demographic characteristics


table 2

Table 2: Details of therapy given per the echocardiographic findings


table 3

Table 3: Response to IVIg-alone without steroids- and factors predicting response to IVIg


Disclosure: M. Agarwal, None; S. Mittal, None; A. Singh, None; N. Agarwal, None; S. Sawhney, None.

To cite this abstract in AMA style:

Agarwal M, Mittal S, Singh A, Agarwal N, Sawhney S. Kawasaki Disease: Is Intravenous Immunoglobulin Alone Adequate for the Child with Kawasaki Disease and Coronary Artery Lesions? A Retrospective Study of 65 Children with Kawasaki Disease from a Single North Indian Centre [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/kawasaki-disease-is-intravenous-immunoglobulin-alone-adequate-for-the-child-with-kawasaki-disease-and-coronary-artery-lesions-a-retrospective-study-of-65-children-with-kawasaki-disease-from-a-single/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/kawasaki-disease-is-intravenous-immunoglobulin-alone-adequate-for-the-child-with-kawasaki-disease-and-coronary-artery-lesions-a-retrospective-study-of-65-children-with-kawasaki-disease-from-a-single/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology